In conclusion, the presented viable strategy not only demonstrates a clinical translational potential of a Wnt inhibitor with remarkable selectivity in suppressing the Wnt/β‐catenin signaling pathway in response to both the acidic microenvironment and MET amplification of the tumor, but also serves as an exemplary demonstration of precision medicine‐guided target discovery and drug development. This evidence concerns the gene MET and neoplasm.